- The Dish’s Weekly Biotechnology News Wrap Up – March 24, 2017Posted 4 days ago
- Laminin cell culture matrices – The key to efficient derivation and reliable culture of stem cells and specialized cells lies within these extracellular matrix proteinsPosted 5 days ago
- Video – Fortem: A platform film built for bioprocessPosted 6 days ago
- The Dish’s Weekly Biotechnology News Wrap Up – March 17, 2017Posted 2 weeks ago
- Cool Tool – The Human Protein AtlasPosted 2 weeks ago
- Optimization of Roche Liberase MNP-S GMP Grade in the Enzymatic Digestion of Human Umbilical Cord for the Isolation of Mesenchymal Stem CellsPosted 2 weeks ago
- Ask the Expert – Maximizing Transient Protein ProductionPosted 2 weeks ago
- The Dish’s Weekly Biotechnology News Wrap Up – March 10, 2017Posted 3 weeks ago
- Enabling Viral Vector Production and Vaccine Manufacturing using the iCELLis – a single-use, automated, and closed manufacturing platformPosted 3 weeks ago
- The Dish’s Weekly Biotechnology News Wrap Up – March 3, 2017Posted 4 weeks ago
First Cell Culture Based Vaccine Plant in the United States
Earlier this week, Novartis announced that their plant in Holly Springs, North Carolina had received Federal approval for the production of influenza vaccines. The one billion dollar facility is the first of its kind in the United States, dedicated to using cell culture techniques to manufacture vaccines instead of the 50 year old conventional egg based technology. This plant joins several European facilities that have already received approval for cell culture based vaccine manufacturing.
The plant is the result of a 25-year public/private partnership between Novartis and the US Department of Health and Human Services (USHHS). In an earlier blog titled “In preparation for the next pandemic,” the Cell Culture Dish discussed the new Novartis facility and the manufacturing improvements to be gained from utilizing cell culture for vaccines. In 2005-2006, USHHS awarded contracts to five companies to improve current vaccine technology and build cell culture based vaccine facilities, of the five Novartis is the only company who carried through and opened a cell culture based plant.
There are several advantages to using a cell-based manufacturing system for vaccines. With cell culture, production begins as soon as a virus strain is identified; there is no need to engineer the virus to grow in eggs. This can cut weeks off total manufacturing time. Officials at USHHS have already mentioned the possibility of using this plant and cell culture based vaccine manufacturing for vaccines against known and emerging infectious diseases. The use of this technology will not be limited to the flu, but could be applied if other pandemics arise. Cell based production also allows manufacturers to increase production quickly and produce more vaccine when compared to egg based technology. USHHS officials have stated that the new Novartis facility could produce up to 25% of the country’s vaccines in the event of a pandemic.
“Today we’re marking the first change in influenza vaccine manufacturing in the United States in 50 years,” said Robin Robinson, Ph.D., director of the Biomedical Advanced Research and Development Authority in HHS’ Office of the Assistant Secretary for Preparedness and Response (ASPR). Robinson led the effort for HHS. “The pandemic readiness of this facility is a major milestone in national preparedness for pandemic influenza and other diseases.”
In the previous blog, I asked, “So are we prepared for the next pandemic?” and I still don’t think that we know the answer. However, facilities like the one in Holly Springs certainly provide USHHS and the Centers for Disease Control more options and more flexibility than relying on egg based production.